Public trading strategy
Eli Lilly's new weight-loss drug crushes expectations — accumulate pharma suppli
Thesis
Eli Lilly's latest drug trial success reinforces its dominance in the massively profitable weight-loss market. Because analysts noted the company's success isn't just built on one single drug, confidence in their entire research pipeline is surging. As the stock builds momentum, it often pulls up the companies that manufacture the drugs and supply the lab equipment, creating a broad buy signal for the sector.
Strategy approach
Develop a breakout strategy for Eli Lilly (LLY) and a key supplier like Thermo Fisher (TMO) on a 1-day timeframe. Enter long if the stock price crosses above the upper Bollinger Band (20, 2) on high volume. Exit if the price closes below the 10-day Exponential Moving Average (EMA), or take profit at a 5% gain.